一名23岁的年轻女士因屈光不正和偏头痛而接受了阿育吠陀治疗。她被带上了ShadbinduTailaNasya,24滴在她的两个鼻孔第二天立即。在表演Nasya的6小时内,病人开始出现发热,最初是低度的,后来,在6小时内,继续高品位。Nasya被停职了,和救援阿育吠陀药物开始,但没有改善。病人后来自行服用了一种退热药,单剂量,高热降到正常。Naranjo药物不良反应概率量表记录给予6分,这表明AE可能是由于ShadbinduTaila的Nasya。该病例报告为Nasya治疗的不良反应(AE)病例报告不足/报告不良的医学数据库增加了证据。它表明,Nasya不是100%的并发症和不良反应免费治疗,但必须极其谨慎。该病例报告强调,在开始Nasya之前也应进行有效的基于阿育吠陀原则的准备治疗,以最大程度地减少不良反应的机会。此病例报告还建议使用测试剂量的Nasya,在开始高剂量之前,从而发现不良事件并预防严重并发症。
A 23 year old young lady was admitted for Ayurveda treatments of her refractive error coupled with migraine. She was put on Shadbindu Taila Nasya, 24 drops in both her nostrils immediately the next day. Within 6 h of performing Nasya, the patient started developing pyrexia which was initially of low grade, and later, within 6 h, went on to high-grade. Nasya was suspended, and rescue Ayurveda medicines were started but had no improvement. The patient later self-medicated an antipyretic drug, and with a single dose, the high-grade pyrexia came down to normal. Naranjo adverse drug reaction probability scale recording gave a score of six, which shows that the AE could be probably due to Nasya with Shadbindu Taila. This
case report adds evidence to the medical database of under-reported/poorly reported adverse effects (AE) cases of Nasya therapy. It shows that Nasya is not a 100 % complication and adverse effect free treatment, but rather has to be done with extreme caution. This
case report highlights that effective Ayurveda principle based preparatory treatments are also to be done before initiating Nasya to minimize the chances of adverse effects. This
case report also suggests practicing a test dose of Nasya, before initiating a high dose, so as to detect adverse events and prevent severe complications.